Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral 18F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Martin Farlow, MD
Primary Investigator
Jessica MacLean
Primary Investigator
Overview
The main reason for you to take part in this study is not to treat you for your condition but to help in answering the following research questions: ? The safety of LY3202626 and any side effects you might have when you take it. ? Whether LY3202626 can help patients with Alzheimer?s disease. ? How much LY3202626 should be given to patients.
Description
The purpose of this study is to assess if inhibiting the production of AB in the brain through BACE1 inhibition with LY3202626 can slow the progression of diseases as assessed by biomarkers of neurodegeneration over 52 weeks of treatment.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Alzheimer's disease
-
Age: Between 55 Years - 85 Years
-
Gender: All